Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals

Study of the Pharmacodynamics of NGM282 on Colonic Transit, Bile Acid Homeostasis, and Fecal Fat in Subjects With Functional Constipation and Healthy Individuals

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02649062

Enrollment

Registered

2016-01-07

Start date

2015-12-31

Completion date

2017-01-31

Last updated

2018-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Constipation

Brief summary

The purpose of this study is to determine the effect of NGM282 on colonic transit, bile acid homeostasis, and fecal fat in subjects with functional constipation and healthy individuals.

Interventions

BIOLOGICALNGM282

OTHERPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Functional constipation confirmed by modified Rome III criteria or Healthy Volunteer

Exclusion criteria

* Structural or metabolic diseases/conditions that affect the GI system * Diagnosis of dyspepsia, IBS, or significant gastrointestinal symptoms

Design outcomes

Primary

Measure	Time frame
Effect on Colon Transit, as measured by the movement of food through the colon	9 days

Secondary

Measure	Time frame
Clinical Laboratory Assessments	14 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026